X4 Pharmaceuticals Stock Analysis

XFOR -  USA Stock  

USD 8.01  0.09  1.11%

The latest X4 Pharmaceuticals price fall may raise some interest from retail investors as it is trading at a share price of 8.01 on 264,300 in trading volume. The company executives were unable to exploit market volatilities in May. However, diversifying your overall positions with X4 Pharmaceuticals can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.91. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from X4 Pharmaceuticals partners.
Check out Your Current Watchlist.

Search Stock Analysis 

The X4 Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about X4 Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. X4 Pharmaceuticals stock analysis module also helps to analyze the X4 Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

X4 Pharmaceuticals Stock Analysis Notes

About 58.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.94. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. X4 Pharmaceuticals recorded a loss per share of 3.1. The entity had not issued any dividends in recent years. The firm had a split on the 14th of March 2019. X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. The company was founded in 2014 and is headquartered in Boston, Massachusetts. X4 Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. For more information please call Paula Ragan at 857 529 8300 or visit http://www.x4pharma.com.

X4 Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. X4 Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding X4 Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
X4 Pharmaceuticals generates negative expected return over the last 90 days
X4 Pharmaceuticals has high historical volatility and very poor performance
X4 Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 3 M. Net Loss for the year was (62.13 M) with profit before overhead, payroll, taxes, and interest of 3 M.
X4 Pharmaceuticals currently holds about 78.71 M in cash with (58.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.53.
Roughly 58.0% of the company outstanding shares are owned by institutional investors
Latest headline from www.marketscreener.com: X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenstrms Macroglobulinemia at EHA 2021 - Marketscreener.com

X4 Pharmaceuticals Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 204.98 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate X4 Pharmaceuticals's market, we take the total number of its shares issued and multiply it by X4 Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (26.39) % which means that it has lost $26.39 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (61.51) %, meaning that it created substantial loss on money invested by shareholders. X4 Pharmaceuticals management efficiency ratios could be used to measure how well x4 pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 17th of June 2021, X4 Pharmaceuticals owns the standard deviation of 4.24, and Market Risk Adjusted Performance of (0.89). In connection with fundamental indicators, the technical analysis model lets you check timely technical drivers of X4 Pharmaceuticals, as well as the relationship between them. Strictly speaking, you can use this information to find out if the entity will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for X4 Pharmaceuticals, which can be compared to its peers in the sector. Please check out X4 Pharmaceuticals market risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if X4 Pharmaceuticals is priced more or less accurately, providing market reflects its prevailing price of 8.01 per share. Given that X4 Pharmaceuticals has jensen alpha of (0.18), we strongly advise you to confirm X4 Pharmaceuticals's latest market performance to make sure the company can sustain itself sooner or later.

X4 Pharmaceuticals Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of X4 Pharmaceuticals more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

X4 Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific X4 Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on X4 Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases X4 Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

X4 Pharmaceuticals Predictive Daily Indicators

X4 Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of X4 Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

X4 Pharmaceuticals Forecast Models

X4 Pharmaceuticals time-series forecasting models is one of many X4 Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary X4 Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About X4 Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how X4 Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling X4 Pharmaceuticals shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as X4 Pharmaceuticals. By using and applying X4 Pharmaceuticals Stock analysis, traders can create a robust methodology for identifying X4 Pharmaceuticals entry and exit points for their positions.
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. The company was founded in 2014 and is headquartered in Boston, Massachusetts. X4 Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding X4 Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Price Transformation Now


Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Module
Check out Your Current Watchlist. Note that the X4 Pharmaceuticals information on this page should be used as a complementary analysis to other X4 Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for X4 Pharmaceuticals Stock analysis

When running X4 Pharmaceuticals stock analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' stock examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Global Correlations
Find global opportunities by holding instruments from different markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
The market value of X4 Pharmaceuticals is measured differently than its book value, which is the value of X4 Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of X4 Pharmaceuticals stock's value that differs from its market value or its book value, called intrinsic value, which is X4 Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because X4 Pharmaceuticals' market value can be influenced by many factors that don't directly affect X4 Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between X4 Pharmaceuticals' stock value and its price as these two are different measures arrived at by different means. Investors typically determine X4 Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, X4 Pharmaceuticals' stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.